A type of virus that preys on bacteria could be harnessed to combat bacterial infections in patients whose immune systems have been weakened by...
Clinical Trials to evaluate effectiveness of anti-malarial drug, hydroxychloroquine (HCQ) and antibiotic, Azithromycin in treating older people with COVID-19 begins in the UK and...
Three adenoviruses used as vectors to produce COVID-19 vaccines, bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of clotting disorders.
Adenovirus...
The disease caused by the novel coronavirus (2019-nCoV) has been given new name COVID-19 by the international body WHO which makes no reference to...
Several new strains of the virus have emerged since the pandemic began. New variants were reported as early as February 2020. The current variant...
Deltacron is not a new strain or variant but a case of co-infection with two variants of SARS-CoV-2. Over the past two years, different...
A plasmid DNA vaccine against SARS-CoV-2 has been found to induce immunity in animal trials. Few other DNA based vaccine candidates are at early stages of...
The infection fatality rate (IFR) is more reliable indicator of the extent of the infection. In this study, the researchers found the actual infection...
Molnupiravir, a nucleoside analog of cytidine, a drug that has shown excellent oral bioavailability and promising results in Phase 1 and Phase 2 trials, could prove...
In countries like UK, USA and Italy which are badly hit by the COVID-19 pandemic, the life expectancy has reduced by at least 1.2-1.3 years.
Diseases...
A recent study suggests increased risk of formation of coronavirus hotspots caused due to deforestation and livestock revolution leading to zoonotic transmission of coronavirus...
What causes severe COVID-19 symptoms? Evidences suggest inborn errors of type I Interferon immunity and autoantibodies against type I Interferon are causal for critical...
Results from the phase2 trial support the view that subcutaneous administration of IFN- β for treatment of COVID-19 enhances speed of recovery and reduces mortality....
A biotech firm, Moderna, Inc. has announced that ‘mRNA-1273’, their mRNA vaccine against novel coronavirus has shown positive results in the phase 1 clinical...
Herd immunity for COVID-19 is said to be achieved when 67% of the population is immune to the virus through infection and/or vaccination, whilst...
The researchers at the Tel-Aviv Sourasky Medical Center have successfully completely Phase I trials for the use of CD24 protein delivered in exosomes to treat COVID-19.
Scientists at...
There has been a rapid increase in the delta variant of SARS CoV-2 in France in June 2021 based on the analysis of 5061 positive...
Findings from recently concluded phase 2 clinical trials in Canada and the UK suggest nitric oxide (NO) could be very helpful in preventing and...
A gene variant of OAS1 has been implicated in reducing the risk of severe COVID-19 disease. This warrants developing agents/drugs that can increase the...
University College London Hospitals (UCLH) has announced neutralising antibody trial against COVID-19. The announcement on 25 December 2020 says ‘’UCLH doses first patient in...
A new global network of laboratories for coronaviruses, CoViNet, has been launched by WHO. The aim behind this initiative is to bring together surveillance...
To protect the NHS and save lives., National Lockdown has been put in place across the UK. People have been asked to stay home...
With the advent of COVID-19, there seems to be a negative selection pressure working against those who may be genetically or otherwise (due to...
NeoCoV, a coronavirus strain related to MERS-CoV found in bats (NeoCoV is not a new variant of SARS-CoV-2, the human coronavirus strain responsible for COVID-19...
There are reports of Russia registering world’s first vaccine against novel corona virus while the phase 3 trial of this vaccine is still in progress. Developed jointly...
English
Afrikaans
Shqip
አማርኛ
العربية
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
简体中文
Corsu
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Filipino
Suomi
Français
Frysk
Galego
ქართული
Deutsch
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
हिन्दी
Hmong
Magyar
Íslenska
Igbo
Bahasa Indonesia
Gaeilge
Italiano
日本語
Basa Jawa
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
한국어
كوردی
Кыргызча
ພາສາລາວ
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Bahasa Melayu
മലയാളം
Maltese
Te Reo Māori
मराठी
Монгол
ဗမာစာ
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
سنڌي
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
O‘zbekcha
Tiếng Việt
Cymraeg
isiXhosa
יידיש
Yorùbá
Zulu